Alliance Pharma plc

LSE APH.L

Alliance Pharma plc EBITDA for the year ending December 31, 2023: USD -36.83 M

Alliance Pharma plc EBITDA is USD -36.83 M for the year ending December 31, 2023, a -344.38% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Alliance Pharma plc EBITDA for the year ending December 31, 2022 was USD -8.29 M, a -119.19% change year over year.
Alliance Pharma plc EBITDA for the year ending December 31, 2021 was USD 43.18 M, a 28.63% change year over year.
Alliance Pharma plc EBITDA for the year ending December 31, 2020 was USD 33.57 M, a -30.64% change year over year.
Alliance Pharma plc EBITDA for the year ending December 31, 2019 was USD 48.40 M, a 36.87% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

LSE: APH.L

Alliance Pharma plc

CEO	Mr. Nicholas John Sedgwick
IPO Date	Nov. 22, 2001
Location	United Kingdom
Headquarters	Avonbridge House
Employees	290
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Key trends

Past 5 years